borg: Göteborgs Universitet 1975.
4. Tisell LE, Jansson S, Nilsson O, Lundberg PA,
Lindstedt G. Sen diagnos av ärftlig medullär thyreoi–
deacancer. Klinisk Kemi i Norden 1997;9(2):35-43.
5.SpencerCA. Thyroglobulin. IBraverman LW,Uti–
ger RD (red.). Werner and lngbar's The thyroid. 7th ed.
Philadelphia:Lippincott-Raven 1995:406-415.
6. Heilig B, HUfnerM, Dörken B, Schmidt-GaykH.
lncreased heterogeneity of serum thyroglobulin in thy–
roid cancer patients as determined by monoclonal an–
tibodies. Klin Wochenschr 1986;64:776-80.
7. SchulzR, BethäuserH, Stempka L,HeiligB,Moll
A, HUfner M. Evidence for immunological differences
between circulating and thyroid tissue-derived thyroglo–
bulin in men. Eur J C1in Invest 1989;
J
9:459-63.
8. OzataM, BayhanH,Bingöl N,DUndar S,Beyhan
Z,Corakci A,GundoganMA. Sequential changes in se–
rum thyroid peroxidase following radioiodine therapy
ofpatientswith differentiated thyroid carcinoma. JC1in
Endocrinol Metab
J
995;80:3634-8.
9. Spencer CA, Takeuchi M, KazarosyanM, Wang
CC,Guttler RB, Singer PA, Fatemi S, LoPrestiS,Nico–
loff
JT.
Serum thyrog1obulin autoantibodies: prevalen–
ce, influence on serum thyroglobu1inmeasurement, and
prognostic significance in patients with differentiated
thyroid carcinoma. J C1in Endocrinol Metab
1998;83:
J
121-7.
JO. Schaadt B, Fe1dt-Rasmussen U, Rasmusson B,
Torring H, Foder B, Jorgensen K, Hansen HS. Assess–
ment of the influence of thyroglobulin (Tg) autoantibo–
dies and other interfering factors on the use ofserumTg
as tumor marker in differentiated thyroid carcinoma.
Thyroid 1995;5:165-70.
l
J.
Black EG, Hoffenberg
R.
Should one measure
serum thyroglobulin in the presence of anti-thyroglo–
bu1in antibodies? Clin Endocrino1 1983;
J
9:597-601.
12. Black EG, Sheppard MC. Serum thyroglobulin
mea-surements in thyroid cancer: evaluation of 'fa1se'
positive results. Clin Endocrino11991;35:519-20.
13. SpencerCA. Recoveries cannot be used toauthen–
ticate thyroglobulin (Tg) measurementswhen sera con–
tainTg autoantibodies. Clin Chem 1996;42:661-3.
14. Mariotti S, BarbesinoG, Caturegli
P,
Marin6M,
Manetti L, Pacini F, Centoni R, Pinchera A. Assay of
thyroglobulin in serum with thyroglobulin au–
toantibodies: an unobtainable goa1? J Clin Endocrinol
Metb 1995;80:468-72.
15. Feldt-Rasmussen U. Analytica1 and clinical per–
formance goals for testing autoantibodies to thyropero–
xidase, thyroglobulin, and thyrotropin receptor. Clin
Chem
J
996;42:
J
60-3.
J
6. SpencerCA,WangCC. Thyroglobulin measure–
ment. Techniques, clinical benefits, and pitfalls. Endo-
132
crinol Metab C1in North Am 1995;24:841-63.
17. Spencer CA, Takeuchi M, KazarosyanM. Cur–
rent status and performance goa1s for serum thyroglo–
bulin assays. C1in Chem 1996;42:164-73.
18. Sapin R, Schlienger JL. Ambiguites des dosages
de thyrog1obuline.Ann Bio! Clin 1998;56: 41-7.
19. Schlumberger M, Eaudin E. Serum thyrog1obu–
lin determination in the foliow-up of patients with dif–
ferentiated thyroid carcinoma. Eur J Endocrino1
1998;138:249-52.
20. Feldt-RasmussenU, Profilis C,Colinet E, Black
E, Bornet H, Bourdoux P et al. Human thyroglobulin
reference material (CRM 457). l st part: Assessment of
homogeneity, stability and immunoreactivity. Ann Bio!
Clin 1996;54:337-42.
21. Pacini F,Mariotti S, Fornica N, Elisei R,Anelli
S, Capotori E, Pinchera A. Thyroid autoantibodies in
thyroid cancer: incidence and re1ationship with tumour
outcome. Acta Endocrinol 1988;119:373-80.
22. RubelloD,CasaraD,GireliiME, PiccoloM,Bus–
nardo B. Clinical meaning of circu1ating antithyroglo–
bulin antibodies in differentiated thyroid cancer: a pro–
spective study. J Nucl Med 1992;33:1478-80.
23. Kumar A, Shah DH, Shrihari U, Dandekar SR,
Yijayan U, Sharma SM. Significance of anti-thyroglo–
bulin autoantibodies in differentiated thyroid carcino–
ma. Thyroid 1994;4: 199-202.
24. Ross DS. Lang-termmanagement ofdifferentia–
ted thyroid cancer. Endocrinol Metab Clin North Am
1990;19:719-26.
25. Roelants Y, De Nayer P, Bouckaert A, Beckers
C.
The predictive value of serum thyroglobulin in the
foliow-up of differentiated thyroid cancer. Eur J Nuc1
Med 1997;24:722-7.
26. Sch1umberger MJ. Papillary and follicular thy–
roid carcinoma. New Engl JMed 1998;338:297-306.
27. Arturi F, Russo D, Giuffrida D et al. Early dia–
gnosis by genetic analysis ofdifferentiated thyroid can–
cermetastases in smalllymph nodes. J C!in Endocrinol
Metab 1997;82: 1638-41.
28. Tallini G, Ghossein RA, Emanuel J et al. Detec–
tion of thyroglobulin, thyroid peroxidase, and RET/
PTC1 mRNA transcripts in the peripheral blood of pa–
tients with thyroid disease. J Clin Oncol 1998;16: l
J
58-
66.
29. Ringel MD, Ladenson PW, Levine MA. Mole–
cular diagnosis of residua! and recurrent thyroid cancer
by amplification ofthyroglobulinmessenger ribonucleic
acid in peripheral blood. J Clin Endocrinol Metab
1998;83:4435-42.
30. HaberRS. The diagnosisofrecurrent thyroid can–
cer- a new approach [Editorial]. J ClinEndocrinol Me–
tab 1998;83:4189-90.
Klinisk Kemi
i
Norden 4. 1998
